|RNS Number : 0795U
Collagen Solutions PLC
13 January 2017
Collagen Solutions Plc
(the "Company" or the "Group")
Awarded third Medical Research Scotland Ph.D. Studentship
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices, research and in-vitro diagnostics, announces that it has been awarded a third Medical Research Scotland Ph.D. studentship, this time in partnership with Professor Elizabeth Tanner, of the School of Engineering, at the University of Glasgow.
The project, titled "Collagen Calcium Phosphate Composite Devices for Bone Augmentation", will investigate the application of collagen fibrils to provide a scaffold for "critical size defects" in bone, which do not heal spontaneously. To obtain healing, some form of scaffold or conduit for the bone repair process is essential and this project will aim to develop novel collagen-containing biomaterials to aid the healing process for these larger bone defects. The project is a four-year Ph.D. project expected to start in the next academic year.
Commenting on the award, Jamal Rushdy, CEO of Collagen Solutions said: "Our current pipeline includes a novel bone graft substitute product, addressing a segment of the $1.7 billion end-user bone graft market opportunity. This new research programme, funded in collaboration with Medical Research Scotland and Professor Tanner's group within the world-class research facilities at the University of Glasgow, will ensure we continue to innovate in this field. In the future we hope to develop next-generation bone graft substitute technologies, addressing more difficult to heal bone defects, thus ensuring continued scientific leadership in this significant segment of the orthobiologics market."
About Professor Elizabeth Tanner, OBE:
Currently Professor of Biomedical Materials at the University of Glasgow, Professor Tanner received an OBE for services to Biomedical Engineering in 2016 and an honorary doctorate within the Faculty of Medicine, Lund University where she is a visiting Professor.
Her research interests are in the development and use of bioactive materials for bone augmentation and replacement, developing composites of polymers filled with bioactive ceramics based on the mineral phase of bone. One such material developed by her team is HAPEX™, used in over half a million patients since 1988. She has published over 150 papers and book chapters and in 2020 she will be President of the 11th World Biomaterials Congress taking place in Glasgow.
About Collagen Solutions:
Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The capabilities of the Company include the provision of native, soluble and powdered collagen formulations, processed and semi-processed tissues such as pericardium, bone, and blood vessels, and expertise in the development and contract manufacture of collagen components for use as engineered tissue scaffolds and other medical devices. These products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology. Collagen Solutions' unique offering extends beyond material supply and contract services through the highly skilled staff who support customers through the various stages of development and regulatory approval. For additional information, please visit www.collagensolutions.com.|
|18BT yes he does... I added yesterday... average down a tad.
And no worries. Steady news flow, and two more customers we know about that they did not announce formerly as an RNS.
We get announcements on timescale for own products, or first contract in China and we will be moving... Just a case of waiting, revenue wise we need to see continued growth, as only blip that I can see is potential slight dilution, if and when cashflow doesn't support the on going short term cash requirements to fund all the avenues and regions of trade... all depends on full year results that one, if we over achieve sales wise it will be slower on no cash burn.|
|jj Agreed - the newsflow should be positive. Jamal comes across well. Thanks for posting|
judging by that, chondromimetic is ready to roll. alongside the CE mark renewal scheduled for mid 2017. The product is ready to be produced in the labs, and there is 6 years worth of existing retrospective customer analysis. Which makes a decent timescale to market for this product, the other pipeline of own brand products (perhaps in conjunction with a partner company) seem to be on the horizon too all of which add high value large margins to the bottom line.
All this on top of organic growth of the production and supply of raw and refined collagen to a growing list of customers and suppliers.
Should get some decent news flow next that will get this moving in a big way, when these items go successfully to market.|
|gnnmartin:Although I am no expert I can confirm following the occasional discussion with Directors of the Company in the past that a "device" is a tested and licensed product such as Chondromimetic which has a collagen base and which performs a specific role such as wound healing , bone remediation or any one of a range of medical functions.These devices take time and expense to produce but if successfully developed and licensed for sale can be sold into the international healthcare market at prices reflecting extremely attractive gross margins.Such margins are far more attractive than those earned on the manufacture and sale of the the basic collagen raw material which is COS's principal activity at the present time.It is for this reason that the Directors of COS are putting so much effort into developing the three devices referred to in the interim statement.Accordingly although we would all like to be seeing early profits and positive net cash flow we will have to wait a little longer whereafter the rewards could be very significant indeed.At that stage such rewards would almost certainly be enhanced by a sale of the Company to a major healthcare business.|
|No idea- guess you will have to go to the city presentation to get the full extent and hyperbole of the 'jam tomorrow' projects|
|What is a "finished device"?|
|Here's what the chairman says:- "We now have greater clarity and visibility not only into our core business and near-term pipeline, but also with respect to specific strategic initiatives. Over the coming years, these initiatives will build upon the strong foundation of customers, people and technologies we have developed since the inception of the Group. In particular I am encouraged by the focus and resource dedication to our three main finished device projects, including the exciting progress being made with ChondroMimetic.
While we are still early in the transformation and acceleration of the Company, I believe we have made prudent investments in our core business and the management team is focused on the right priorities for sustainable growth towards our goals for this fiscal year.
In the longer term, I feel confident that our target of 5x revenue within 5 years is achievable, based upon the strategy that the management team is executing against.
I continue to be excited about the vision for Collagen Solutions to become the industry's first choice for regenerative biomaterials and thank you for your support."
I used to have a boss, a Californian, that spoke like this. Tedious, repetitive, meaningless words. I started yawning by paragraph 2. After waiting for some decent newsflow this is just plain Boring!|
|Interims read OK, but little feel for when they expect profitability and when they will run out of cash|
|Collagen Solutions PLC Notice of Results
UK Regulatory (RNS & others)
RNS Number : 7679Q
Collagen Solutions PLC
02 December 2016
Collagen Solutions Plc
(the "Company" or the "Group")
Notice of Half Year Results
The Board of Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, will announce their unaudited interim results for the six months ending 30 September 2016 on Monday, 19 December 2016.
A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 10.00am on Monday 19 December 2016.
If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected]com.|
|this is just going to drift down coz investors are going to get fed up waiting for this to move and go to pastures new and l might be one of them.|
|Why does chairman receive shares when the company makes an acquisition?...|
the ghost who walks
|Couldnt agree more inter. GEC is a prime example where we could have made some dosh with day trading but waiting for this to move, the oportunity has passed me by.|
|Petewy- please note the date when this 'buy' rating was issued and compare the price target to where we are today. Stocks like this drive me nuts. I mean they promise much and there are some serious new technology areas emerging where canny investors can place a modest stake and perhaps hope to get ten bagger - or more- returns. Or you could study the form book and back a horse. The gates open and within a short while you know if you've won or lost and have some excitement on the way. But companies like COS just keep you hanging on... and on.... and on and faithful investors hang on .... and on.... and meanwhile other opportunities are slipping by, the grandchildren are growing up, the grim reaper is knocking on your door, the grass needs trimming 'cos it's growing faster than your stock and life just passes by. My plea to the management team? For God's sake guys- DO SOMETHING|
|Google search produced:
8/11/2015 – Collagen Solutions had its “Buy” rating reiterated by analysts at Panmure Gordon. They now have a GBP 18.00p price target on the stock.
Only one stockbroker quote.|
|l've got snails that move quicker than this.|
|anyone go to agm and pick anything up ? Feedback ongoing business etc? Cheers|
|This share needs news to give it a boost.|
|Kicking in again .. Already rosey platform but plenty potentials out there that will change bottom line ... And make cos fly.. I look forward to seeing story unfold further.. As I've said before long term hold . Dyor|
|Move up soon imo|
|Below is quote from Hardman and Co report July 19th
Valuation: Our DCF valuation has risen 16% to £54m or 32p per share on the
back of these improved results. There are few quoted competitors that could be
considered as comparator companies for valuation purposes. The closest,
Innocoll, is developing proprietary products and commands an EV of £140m.|
|babbler- where did you get valuation at 32p from?|